For Immediate Release

Company Name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code Number: 4568, First Section, Tokyo, Osaka, Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Partial Correction to Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2009
(Correction of Text and Figures)

Tokyo, February 12, 2009 – Daiichi Sankyo Company, Limited today announces it has made partial corrections to the content of “Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2009,” announced on January 30, 2009. The parts that have been corrected are shown by underlined text.


[Before correction]
(1) Significant changes in subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation): No

[After correction]
(1) Significant changes in subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation): Yes
New: 2 companies: (Company names: Solrex Pharmaceuticals Co., Ranbaxy (Netherlands) B.V.)
Excluded: 0 companies: (Company name: - )
Note: Please see 4. Other Matters, Qualitative Information/Financial Statements, etc. on page 5 for further details.

2. Page 5, “4. Other Matters” in “Qualitative Information / Financial Statements, etc.”

[Before correction]
(1) Significant changes in subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation)
There are no relevant matters to report.
(1) Significant changes in subsidiaries during the period (changes in specified subsidiaries resulting in a change in scope of consolidation)

The two companies, Solrex Pharmaceuticals Co., and Ranbaxy (Netherlands) B.V., have newly become specified subsidiaries.

These changes are made since the amount of capital of each company, which became subsidiaries due to the Company's acquisition of shares of Ranbaxy, is equivalent to 10% or more of the Company's capital.


[Before Correction]

(1) Consolidated Balance Sheets

(Millions of yen)

<table>
<thead>
<tr>
<th></th>
<th>As of December 31, 2008</th>
<th>As of March 31, 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Summary)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convertible bonds</td>
<td>46,500</td>
<td>–</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>16,664</td>
<td>18</td>
</tr>
</tbody>
</table>

[After Correction]

(1) Consolidated Balance Sheets

(Millions of yen)

<table>
<thead>
<tr>
<th></th>
<th>As of December 31, 2008</th>
<th>As of March 31, 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Summary)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-current liabilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convertible bond-type bonds with subscription rights to shares</td>
<td>46,500</td>
<td>–</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>16,664</td>
<td>18</td>
</tr>
</tbody>
</table>

Please click the below web link for the corrected "Financial Results 3Q of Fiscal 2008".